Cost Curve

Should a Lack of Pharmaceutical Reform Alliance Disclosure Erode Confidence in the Research It Sponsors?

Brian Reid

PhRMA Suit to Stop MFN Prices in Medicare Has Broader Implications

And HHS data shows the impact of restricting Medicare spending on 340B drugs

Brian Reid

The Pharmaceutical Reform Alliance’s Backing Remains a Mystery, Even To Its Supporters

Brian Reid

KFF Poll Finds 36% of Americans Support Burning the U.S. Healthcare System to the Ground

And a PBM-linked Pharmaceutical Reform Alliance member with a questionable understanding of the PBM industry

Brian Reid

The Strangest ‘Member’ of the Pharmaceutical Reform Alliance, According to Curve Readers

And Americans from all political persuasions appear to agree on one thing: hatred of PBMs

Brian Reid

Hospitals Received $244 Billion for 340B Drugs Last Year, Pocketing $142 Billion in Profit

And I need your vote in a very, very important poll

Brian Reid

The CMS Rules Bringing International Prices to Medicare Are Essentially Meaningless

And a not-very-insightful launch price paper has a not-very-transparent funding source

Brian Reid

PhRMA Selects Its Next CEO: Former Congressional Heavyweight Eric Cantor

And companies with new meds are (again) getting shy about revealing prices at approval

Brian Reid

Seniors Probably Won’t Be Happy About 2027 Medicare Choices (Even Though CMS Is Celebrating Lower Premiums)

Plus 84 pages on what the Democrats will do on healthcare if they retake the House

Brian Reid